Watch out for ‘counterfeit’ batch of rabies vaccine: Drug regulator to states
Source Entity
Anonna Dutt
Authorities have launched a probe after discovering a counterfeit batch of the widely used Abhayrab rabies vaccine in Delhi. Testing revealed significant discrepancies in packaging and potency, leading to four arrests and a nationwide alert to state regulators.
Investigation into Spurious Rabies Vaccine Racketeering
The Discovery of Counterfeit Medical Supplies
In a concerning development for public health, authorities have uncovered a sophisticated racket involving the distribution of counterfeit rabies vaccines. The Central Drugs Laboratory (CDL) in Kasauli, Himachal Pradesh, officially classified a specific batch of Abhayrab vaccine—batch number KE25012—as "not of standard quality" (NSG) and "misbranded" after it failed critical potency testing. This discovery originated from a joint enforcement operation conducted by the Delhi Police and the Delhi Drugs Control Department at an unlicensed residential premise in Mukherjee Nagar, North Delhi, back in April.
Identifying the Counterfeit Discrepancies
The investigation revealed that the seized vials were sophisticated imitations that deviated significantly from genuine products manufactured by Indian Immunologicals Ltd (IIL). Forensic and regulatory analysis highlighted at least 17 distinct differences between the fake vials and genuine samples. These discrepancies included obvious errors in typography and labeling, such as the misspelling of "L Pasteur" as "L Posteur" and the misuse of punctuation. Furthermore, the counterfeit products exhibited irregularities in QR-code verification, cap coloration, font spacing, and the company logo, which served as clear indicators that the product did not originate from the authorized manufacturing facilities.
Broader Implications for Public Health
Abhayrab holds a significant position in the Indian pharmaceutical landscape, accounting for approximately 40% of the domestic market share for rabies vaccines. The infiltration of a spurious version of such a widely utilized vaccine poses a severe threat to patients who rely on these immunizations for post-exposure prophylaxis. Rabies is a fatal disease, and the administration of a non-potent, "misbranded" vaccine could leave patients completely unprotected, potentially leading to tragic outcomes for those who believe they have been vaccinated against the virus.
Regulatory Response and Law Enforcement
Following the confirmation of the fraud, the Central Drug Standards and Control Organisation (CDSCO) has issued a nationwide advisory to all state drug regulators. This directive mandates increased vigilance to identify and remove any remaining units of batch KE25012 from the supply chain. The Delhi Police, through their Crime Branch, have already taken decisive action by arresting four individuals linked to the manufacturing and distribution of these fake vials. The ongoing investigation aims to dismantle the supply network that allowed these products to enter the market.
Future Trends and Systemic Safeguards
The incident underscores the critical necessity for robust oversight within the pharmaceutical supply chain. As counterfeiters employ increasingly deceptive tactics—such as residential-based "manufacturing" hubs—regulatory bodies must enhance their surveillance and enforcement capabilities. The integration of more secure, tamper-proof authentication technologies and greater coordination between state and central authorities will be essential to prevent future incursions into the medical supply chain. Maintaining public trust in essential vaccines requires constant vigilance and the swift prosecution of those who compromise the safety of life-saving medical products.